22 Jan Mitch Scanlan Appointed New CEO of Biogelx Limited
Glasgow, Scotland, 18th January 2018 – Biogelx Limited has announced the appointment of Mitch Scanlan as their new CEO. He assumed responsibilities on the 3rd January 2018 and has succeeded David Lightbody the founding CEO who has stepped down from the position as Biogelx accelerate the commercialisation of its 3D Biomaterial technology platform. The company will continue to be headquartered and expand its activities at Biocity Glasgow which provides an excellent environment and infrastructure for the company to develop and expand.
Mitch has extensive experience and a proven track record of driving commercial growth for a range of companies within the life sciences sector including Sartorius Stedim Biotech, Merck Millipore, Quintiles and Deloitte & Touche. In his most recent position Mitch led the sales and marketing activities of one of Scotland’s most successful life science start-ups BioOutsource Limited, who over 8 years grew from 15 to 180 people and were successfully acquired and integrated into Sartorius Stedim Biotech in April 2015.
Mitch commented: “This is a very exciting time to be joining Biogelx, the company has created an innovative and differentiated synthetic hydrogel technology platform which is well placed to become an essential ingredient to support a range of 3D cell culture applications including 3D Bioprinting, Tissue Engineering and Regeneration. In addition to selling our existing portfolio of products we are actively looking to collaborate with commercial partners to develop new 3D biomaterial solutions to support a range of high growth applications.”
Toby Reid Managing Director for BioCity Group said “it’s great to see an experienced commercial executive like Mitch join our portfolio of companies at BioCity, Glasgow and lead them through the next phase of their commercial development”